ID 110348
Title Transcription
シュジュツ フノウ シンコウ イガン ニ タイスル カガク リョウホウ
Title Alternative
Chemotherapy for unresectable gastric cancer
Author
Takayama, Tetsuji Department of Gastroenterology and Oncology Institutes of Health Biosciences, the University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Kimura, Tetsuo Department of Gastroenterology and Oncology Institutes of Health Biosciences, the University of Tokushima Graduate School KAKEN Search Researchers
Kitamura, Shinji Department of Gastroenterology and Oncology Institutes of Health Biosciences, the University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Aoyagi, Eriko Department of Gastroenterology and Oncology Institutes of Health Biosciences, the University of Tokushima Graduate School
Miyamoto, Hiroshi Department of Gastroenterology and Oncology Institutes of Health Biosciences, the University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Keywords
gastric cancer
chemotherapy
molecular targeting drug
predictive marker
Content Type
Journal Article
Description
Although the incidence of gastric cancer is declining in Japan, it is still the second common cancer. After 2000 year, several new anticancer drugs for gastric cancer have been developed, and overall response rate and survival have been 7‐51% and 6‐12 months respectively. However, these are still unsatisfactory results and the majority of the metastatic gastric cancer is incurable. We proposed a triplet regimen consisting of docetaxel, cisplatin and S‐1(DCS), and performed phase I and II study. The results showed that response rate was87.1% and overall survival was 22 months. Now, phase III study is under way. In addition, recently efficacy of herceptin, an antibody agent against HER2, was proved for HER2 positive gastric cancer. This is the first molecular targeting drug that was approved for gastric cancer. In future, combination of herceptin and cytotoxic anticancer drugs such as DCS regimen will be tested.
Journal Title
四国医学雑誌
ISSN
00373699
NCID
AN00102041
Publisher
徳島医学会
Volume
67
Issue
1-2
Start Page
25
End Page
28
Sort Key
25
Published Date
2011-04-25
FullText File
language
jpn
TextVersion
Publisher
departments
Medical Sciences
University Hospital